Attorney Docket No. 4343.214-US Patent Application entitled: "Protracted GLP-1 Compositions" Applicants: Jensen et al.

The USFTO hereby acknowledges receipt of the following:

Express Mail Certificate

Application Fee Transmittal (in duplicate)

Patent Application

Copy Executed Combined Declaration and Power of Attorney

Preliminary Amendment Information Disclosure Statement

PTO-1449 Form

VGre/SGon January 23, 2001

and commence and a comparison of the comparison of the commentation of the commentatio

The second of the second of the second of the second of

VIA US Express Mail, label no. EL636736819US

Patent Application entitled: "Protracted GLP-1 Compositions" Applicants:

The USPTO hereby acknowledges receipt of the following:

- Express Mail Certificate
 Application Fee Transmittal (in duplicate) Copy Executed Combined Declaration and Power of Attorney

Preliminary Amendment

- Information Disclosure Statement
- PTO-1449 Form

VGre/SGon January 23, 2001

VIA US Express Mail, label no.

EL63673683.905

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application Commissioner for Patents Washington, DC 20231

Re: U.S. Patent Application for

Title: Protracted GLP-1 Compositions

Applicants: Jensen et al.

Sir:

Express Mail Label No. EL636736819US

Date of Deposit: January 23, 2001

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Copy of Executed Combined Declaration and Power of Attorney
- 4. Preliminary Amendment
- 5. Information Disclosure Statement
- 6. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvia Gonzalez

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212)867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application Commissioner for Patents Washington, DC 20231

Express Mail Label No. EL636736819US Date of Deposit <u>January 23, 2001</u>

Sir:

of

This is a request for filing a continuation application under 37 C.F.R. 1.53(b)

Applicant(s): Jensen et al.

Title: Protracted GLP-1 Compositions

- 11 pages of specification 0 sheets of Formal Drawings
- 2 sheets of Declaration and Power of Attorney
- [x] The filing fee is calculated as follows:

Basic Fee: \$710.00

Total Claims: $13 - 20 = 0 \times 18 =$

Independent Claims: $1 - 3 = 0 \times 80 =$ \$0

Total Fee: \$710.00

Priority of Danish application no. 1478/94 filed on December 23, 1994 is claimed under 35 U.S.C. 119. A certified copy was filed with U.S. Serial No: 08/860,103 filed on June 17, 1997.

The benefit of application no. 08/860,103 filed on June 17, 1997 in the U.S. and PCT/DK95/00516 filed on December 21, 1995, via the PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$710, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 23, 2001

Valeta A. Gregg, Reg. No. 35,127

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123